Roche (VTX:ROG) has been assigned a CHF 305 price objective by investment analysts at Barclays in a research note issued on Wednesday, December 27th. The brokerage currently has a “buy” rating on the healthcare company’s stock. Barclays’ price target indicates a potential upside of 24.08% from the company’s current price.
Several other research analysts have also commented on ROG. Goldman Sachs Group set a CHF 325 price objective on shares of Roche and gave the stock a “buy” rating in a report on Thursday, September 21st. JPMorgan Chase & Co. restated a “buy” rating on shares of Roche in a report on Monday, October 2nd. Kepler Capital Markets set a CHF 230 target price on shares of Roche and gave the stock a “neutral” rating in a research report on Monday, September 11th. Sanford C. Bernstein set a CHF 262 target price on shares of Roche and gave the stock a “buy” rating in a research report on Friday, December 1st. Finally, Jefferies Group set a CHF 290 target price on shares of Roche and gave the stock a “buy” rating in a research report on Thursday, September 21st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of CHF 263.42.
Shares of Roche (VTX ROG) traded up CHF 1.30 during midday trading on Wednesday, reaching CHF 245.80. 1,680,000 shares of the company’s stock traded hands, compared to its average volume of 1,550,000. Roche has a 1-year low of CHF 226.10 and a 1-year high of CHF 273. The company has a market cap of $212,060.00 and a price-to-earnings ratio of 21.85.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.